US 11,959,903 B2
Organotypic DRG-peripheral nerve culture system
Curt Deister, Alachua, FL (US)
Assigned to Axogen Corporation, Alachua, FL (US)
Filed by AXOGEN CORPORATION, Alachua, FL (US)
Filed on Sep. 17, 2021, as Appl. No. 17/478,057.
Application 17/478,057 is a division of application No. 14/724,365, filed on May 28, 2015, granted, now 11,156,595.
Prior Publication US 2022/0003742 A1, Jan. 6, 2022
Int. Cl. G01N 33/483 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01R 33/56 (2006.01); G01R 33/563 (2006.01)
CPC G01N 33/4833 (2013.01) [G01N 33/5026 (2013.01); G01N 33/56966 (2013.01); G01R 33/5608 (2013.01); G01R 33/56341 (2013.01)] 22 Claims
 
1. A method for testing the effect of a condition on nerve outgrowth, the method comprising:
treating a nerve graft in accordance with a study protocol, the study protocol comprises one or more of:
submerging the nerve graft in a solution comprising a test compound,
dosing the nerve graft with radiation or heat,
mechanically modifying the microstructure or macrostructure of the nerve graft,
dosing the nerve graft with an outgrowth promoting agent or an outgrowth inhibiting agent,
applying an electrical field to the nerve graft, and
seeding the nerve graft with stem cells or Schwann cells;
affixing a dorsal root ganglion (DRG) to a first end of the nerve graft to form a test construct;
culturing the test construct in a medium for a period of time to allow nerve outgrowth from the DRG into the nerve graft; and
performing an analysis of the test construct to determine an amount of an outgrowing nerve structure.